Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing

Indivior Pharmaceuticals, Inc.

Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.
Mark Crossley stepped down as CEO and director; separation terms previously filed.
Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.
All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.
New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1.

item 5.02 item 1.01 item 5.03 item 5.07 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001625297-25-000032
form_type: 8-K
ticker: INDV
cik: 0001625297
company_name: Indivior Pharmaceuticals, Inc.
filed_at: 2025-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.104915+00:00
generated_at: 2026-05-22T04:36:32.458892+00:00
sec_items: ["5.02", "1.01", "5.03", "5.07", "7.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001625297-25-000032
json_url: https://secwatch.observer/filing/0001625297-25-000032.json
markdown_url: https://secwatch.observer/filing/0001625297-25-000032.md
text_url: https://secwatch.observer/filing/0001625297-25-000032.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/indv-20250508.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Crossley

Chief Executive Officer

INDV · Indivior Pharmaceuticals, Inc.

Effective: 2025-05-08
Successor: Joe Ciaffoni
Filed: May 08, 2025 23:59 UTC

Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.

Appointed

Joe Ciaffoni

Chief Executive Officer

INDV · Indivior Pharmaceuticals, Inc.

Effective: 2025-05-08
Filed: May 08, 2025 23:59 UTC

Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.

Source-grounded claims

ce85a30096

Mark Crossley departed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..

Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

fa9a64af69

Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..

Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0001625297-25-000032

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.